Cargando…

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446381/ https://www.ncbi.nlm.nih.gov/pubmed/22420423 http://dx.doi.org/10.1186/bcr3147

Ejemplares similares

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
por: Chrisanthar, Ranjan, et al.
Publicado: (2008)

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011)

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
por: Knappskog, Stian, et al.
Publicado: (2015)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
por: Mathiesen, Randi R, et al.
Publicado: (2012)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour
por: Straume, Anne Hege, et al.
Publicado: (2012)

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
por: Yndestad, Synnøve, et al.
Publicado: (2017)

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
por: Yndestad, Synnøve, et al.
Publicado: (2017)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
por: Lønning, Per Eystein, et al.
Publicado: (2018)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
por: Huun, Johanna, et al.
Publicado: (2017)

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions
por: Nikolaienko, Oleksii, et al.
Publicado: (2021)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
por: Nikolaienko, Oleksii, et al.
Publicado: (2023)

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
por: Southey, Melissa C, et al.
Publicado: (2016)

Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model
por: Lee, Andrew J., et al.
Publicado: (2016)

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
por: Synnestvedt, Marit, et al.
Publicado: (2012)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
por: Eikesdal, Hans P., et al.
Publicado: (2014)

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
por: Helle, S I, et al.
Publicado: (2001)

Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011)

Constitutional Mosaic Epimutations - a hidden cause of cancer?
por: Lønning, Per E., et al.
Publicado: (2019)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2020)

Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2021)

Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks
por: Decker, Brennan, et al.
Publicado: (2017)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D
por: Graffeo, R., et al.
Publicado: (2022)

Regional radiotherapy after primary systemic treatment for cN+ breast cancer patients
por: Boersma, Liesbeth J., et al.
Publicado: (2023)

Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors
por: Paukovcekova, Silvia, et al.
Publicado: (2022)

MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
por: Knappskog, Stian, et al.
Publicado: (2012)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
por: Gallagher, Shannon, et al.
Publicado: (2021)

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n13r785uijapdr2j1j89f8mpfv